Year None2024202320222021202020192018201720162015 Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) June 7, 2024 at 5:59 PM EDT Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference May 29, 2024 at 4:01 PM EDT Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 9, 2024 at 4:01 PM EDT Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 6, 2024 at 4:05 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) April 8, 2024 at 4:01 PM EDT Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update March 14, 2024 at 4:01 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) March 8, 2024 at 4:05 PM EST Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference February 28, 2024 at 4:01 PM EST Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis February 26, 2024 at 6:30 PM EST Pagination First page « first Previous page ‹ previous Page 1 Current page 2
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference May 29, 2024 at 4:01 PM EDT
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 9, 2024 at 4:01 PM EDT
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update March 14, 2024 at 4:01 PM EDT
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference February 28, 2024 at 4:01 PM EST
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis February 26, 2024 at 6:30 PM EST